|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2010-3-1
|
|
pubmed:abstractText |
Synthetic oligodeoxynucleotides (ODN) containing unmethylated CpG motifs mimic the immunostimulatory activity of bacterial DNA. CpG ODN directly stimulate B cells and plasmacytoid dendritic cells (pDC), promote the production of Th1 and pro-inflammatory cytokines, and trigger the maturation/activation of professional antigen presenting cells. CpG ODN are finding use as vaccine adjuvants, where they increase the speed, magnitude and duration of vaccine-specific immune responses. For example, CpG ODN significantly prolong the protection induced by AVA (Anthrax Vaccine Adsorbed). Unexpectedly, a majority of animals immunized with CpG-adjuvanted AVA maintain resistance to anthrax infection even after their Ab titers decline to sub-protective levels. This survival is mediated by the de novo production of protective Abs by high affinity long-lived memory B cells. The immunostimulatory activity of CpG ODN was probed at the molecular level by microarray. Results show that a small group of 'inducers' rapidly up-regulated a large network genes following CpG treatment of mice. This stimulatory activity is quenched by 'suppressors' that down-regulate the expression of targeted genes, including most of the 'inducers'. These findings shed light on the mechanism underlying CpG-mediated immune activation and therapeutic activity.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/20188247-11130078,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20188247-11290780,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20188247-11561001,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20188247-11564765,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20188247-11592079,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20188247-11726956,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20188247-11738765,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20188247-11970999,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20188247-11994506,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20188247-12119352,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20188247-15246624,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20188247-15664922,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20188247-16930709,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20188247-17145935,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20188247-17607015,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20188247-17913545,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20188247-18832738,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20188247-7700380,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20188247-8548847,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20188247-8610135,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20188247-8757300,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20188247-8757335,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20188247-8783641,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20188247-9682382,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20188247-9794366,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20188247-9858519
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1873-2518
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Published by Elsevier Ltd.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
23
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1919-23
|
|
pubmed:dateRevised |
2011-7-25
|
|
pubmed:meshHeading |
pubmed-meshheading:20188247-Adjuvants, Immunologic,
pubmed-meshheading:20188247-Animals,
pubmed-meshheading:20188247-Anthrax,
pubmed-meshheading:20188247-Anthrax Vaccines,
pubmed-meshheading:20188247-Antibodies, Bacterial,
pubmed-meshheading:20188247-B-Lymphocytes,
pubmed-meshheading:20188247-Cytokines,
pubmed-meshheading:20188247-Dendritic Cells,
pubmed-meshheading:20188247-Gene Expression Regulation,
pubmed-meshheading:20188247-Gene Regulatory Networks,
pubmed-meshheading:20188247-Immunologic Memory,
pubmed-meshheading:20188247-Mice,
pubmed-meshheading:20188247-Mice, Inbred A,
pubmed-meshheading:20188247-Mice, Inbred BALB C,
pubmed-meshheading:20188247-Oligodeoxyribonucleotides,
pubmed-meshheading:20188247-Oligonucleotide Array Sequence Analysis,
pubmed-meshheading:20188247-Th1 Cells
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Immunostimulatory CpG oligonucleotides: Effect on gene expression and utility as vaccine adjuvants.
|
|
pubmed:affiliation |
Cancer and Inflammation Program, National Cancer Institute, Frederick, MD 21702, United States. klinmand@mail.nih.gov
|
|
pubmed:publicationType |
Journal Article
|
